ASN: Elderly with chronic kidney disease benefit from SGLT2 inhibitors
Sodium-glucose cotransporter 2 (SGLT2) inhibitors show significant benefits for adults aged 80 years and older with chronic kidney disease (CKD), according to a study presented at Kidney Week, the annual meeting of the American Society of Nephrology, held from Oct. 21 to 25 in Denver.
A recent study presented at Kidney Week, the annual meeting of the American Society of Nephrology, highlights the significant benefits of SGLT2 inhibitors for elderly adults with chronic kidney disease (CKD), specifically those aged 80 years and older. Led by Dr. Julian Doricic from Medizinische Hochschule Hannover, Germany, the research analyzed data from the TriNetX database, comparing 23,765 SGLT2 inhibitor users with nonusers in the same age group.
After a two-year follow-up period, the researchers found that patients treated with SGLT2 inhibitors experienced a significant reduction in mortality risk, with an adjusted hazard ratio (aHR) of 0.734. This benefit was observed across all predefined subgroups. Furthermore, SGLT2 inhibitor users demonstrated a lower risk of major adverse cardiovascular events (aHR of 0.884) and major adverse kidney events (aHR of 0.775) compared to non-users.
The study underscores the importance of carefully assessing the risks and benefits for the very elderly, who are often underrepresented in large-scale randomized controlled trials due to multimorbidity and frailty. As Dr. Bernhard M.W. Schmidt from Hannover Medical School, Germany, noted, "These patients require a careful, individualized risk-benefit assessment and close clinical monitoring."
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
